The U.S. Food and Drug Administration (FDA) warned about the safety risks of using compounded or custom-made versions of popular weight-loss drugs such as Wegovy and diabetes drug Ozempic.
New highly-effective weight loss drugs such as Novo Nordisk's Wegovy are not a “silver bullet” for addressing the rapid rise in global obesity rates, the World Health Organization’s nutrition chief told Reuters, as the agency conducts its first review of obesity management guidelines in more than 20 years.
New highly-effective weight loss drugs such as Novo Nordisk s (NOVOb.CO) Wegovy are not a “silver bullet” for addressing the rapid rise in global obesity…
Novo Nordisk’s Wegovy won U.S. approval in June 2021 with a label that says it can be used for chronic weight management in patients with a body mass index (BMI) of 27 or more who have at least one weight-related ailment, or in any patient with a BMI of 30 or greater.